Company

Bank

Analyst

Coverage

Opinion

Wk chg

9/14 cls

Amgen Inc. (NASDAQ:AMGN)

Baird

Christopher Raymond

Downgrade

Neutral (from outperform)

-3%

$81.36

Raymond said Amgen's story is "largely played-out" in the near/intermediate term, but raised his target to $84 from $83 based on a 12.5x multiple to his 2013 EPS estimate of $6.99. Raymond noted Amgen's stock price has increased more than 75% since August 2011, and added that the company is near the end of its stock repurchase plan, which he believes has been a key driver of the company's price in recent quarters. Raymond said value-enhancing pipeline events are still "a ways off."

Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY)

Bloom Burton

Philippa Flint

Price target

Buy

-17%

C$2.33